Drugs / IMAPRELIMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02630901 | Mar 2016 → Feb 2018 | psoriasis | Prothena Biosciences Ltd. | Completed | Met primary |
| Phase 1 | NCT02458677 | May 2015 → Feb 2016 | psoriasis | Prothena Biosciences Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2017-11-07 | Prothena Biosciences Ltd. | Results Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update prothena.com ↗
However, the clinical results in this study did not meet the pre-specified criteria for evidence of a well-defined relationship between biological activity and meaningful clinical effects required to advance PRX003 into mid-stage clinical development for psoriasis or psoriatic arthritis as previously planned. |
| 2017-09-28 | Prothena Biosciences Ltd. | Results Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis prothena.com ↗
In this study, PRX003 administration resulted in dose- and time-dependent occupancy and downregulation of CD146 on Th17 cells, consistent with prior Phase 1a SAD study results. |
| 2016-08-02 | Prothena Biosciences Ltd. | Results Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update prothena.com ↗
Presented clinical results from PRX003 Phase 1 single ascending dose study, demonstrating target engagement of novel anti-MCAM antibody for inflammatory diseases |
| 2016-06-09 | Prothena Biosciences Ltd. | Results Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases prothena.com ↗
Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced new clinical results from a Phase 1 double blind, placebo controlled, single ascending dose study of PRX003 in healthy volunteers. |
| 2016-02-29 | Prothena Biosciences Ltd. | Results Prothena to Present Preclinical Data for PRX003 at 2016 AAAAI Annual Meeting prothena.com ↗
Preclinical data demonstrating the ability of PRX003 to inhibit migration of disease causing immune cells will be featured in the following poster presentation: |
All press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMAPRELIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650506 ↗ |
| Known as | PRX003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02458677 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650506 ↗ |
| Route | Intravenous | “PRX003 Administered by Intravenous Infusion in Healthy Subjects” NCT02458677 ↗ |